Viracta Therapeutics Reported Phase 2 NAVAL-1 Trial Results From Stages 1 And 2 Of The Relapsed Or Refractory Epstein-Barr Virus-Positive Peripheral T-cell Lymphoma Cohort
Portfolio Pulse from Benzinga Newsdesk
Viracta Therapeutics reported positive Phase 2 NAVAL-1 trial results for its treatment of relapsed or refractory Epstein-Barr Virus-Positive Peripheral T-cell Lymphoma. The company also received productive feedback from the FDA, providing clarity on the regulatory path for Nana-val. Viracta plans to begin a randomized controlled trial in the second half of 2025.
August 14, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viracta Therapeutics reported positive Phase 2 trial results for its treatment of relapsed or refractory Epstein-Barr Virus-Positive Peripheral T-cell Lymphoma and received FDA feedback on the regulatory path for Nana-val. The company plans to start a randomized controlled trial in the second half of 2025.
The positive Phase 2 trial results and FDA feedback are significant milestones for Viracta Therapeutics. These developments increase the likelihood of regulatory approval and future commercialization of Nana-val, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100